After-Hours Stock Movers 05/27: (PHAS) (SMTC) (TOL) Higher; (IOVA) (ARNA) (PLT) Lower (more...)

Iovance Biotherapeutics (IOVA) Highlights Updated Clinical Data for Tumor Infiltrating Lymphocyte Therapy Lifileucel in Advanced Melanoma

May 29, 2020 8:04 AM EDT

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncologys (ASCO) ASCO20 Virtual Scientific Program.

We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program, said Maria Fardis, Ph.D., President and Chief... More

Iovance Biotherapeutics (IOVA) Prices 16.935M Share Common Offering at $31/Sh

May 29, 2020 5:52 AM EDT

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $525 million. In... More

Call Buying Activity Continues in BioCryst Pharma (BCRX), Targeting Upside in Shares Through July -Susquehanna

May 28, 2020 3:01 PM EDT

Susquehanna options strategist Alison Edwards notes call buying activity in BioCryst Pharma (NASDAQ: BCRX), as investors bought ~12k July 9 calls, adding to roughly 20K of the calls bought since early last week. A position of about 30k calls gives investors the right... More

Craig-Hallum Upgrades Box, Inc. (BOX) to Buy

May 28, 2020 8:56 AM EDT

Craig-Hallum analyst Chad Bennet upgraded Box, Inc. (NYSE: BOX) from Hold to Buy with a price target of $24 (from $18).

Improved Execution, Net Expansion, AndOPM AccelerationCreate A Great Risk/Reward

For an analyst ratings summary and ratings history on... More

Workday (WDAY) PT Raised to $190 at Oppenheimer Following 1Q

May 28, 2020 8:53 AM EDT

Oppenheimer analyst Brian Schwartz raised the price target on Workday (NASDAQ: WDAY) to $190.00 (from $165.00) while maintaining an Outperform rating following the company's 1Q earnings report. Total revenue of ~$1,018M was ~$15M above the $1,003M consensus; and PF EPS of $0.44 was $0.04 below the $0.48 consensus.

The... More

Semtech Corp. (SMTC) PT Raised to $60 at Oppenheimer Following 1Q

May 28, 2020 8:47 AM EDT

Oppenheimer analyst Rick Schafer raised the price target on Semtech Corp. (NASDAQ: SMTC) to $60.00 (from $52.00) while maintaining an Outperform rating following the company's 1Q earnings report. The company reported beat/ raise results, despite COVID-19 and the loss of Huawei. 1Q sales/EPS of $133M/$0.35... More

Box, Inc. (BOX) PT Raised to $22 at Oppenheimer Following Solid 1Q

May 28, 2020 8:43 AM EDT

Oppenheimer analyst Ittai Kidron raised the price target on Box, Inc. (NYSE: BOX) to $22.00 (from $16.00) while maintaining a Outperform rating following the company's 1Q earnings report. Box's results of $183.6M/$0.10 compared favorably to the Street's $182.0M/$0.05E with billings of $128.1M vs.... More

Arena Pharma (ARNA) Prices 5.5M Share Common Offering at $50/Sh

May 28, 2020 8:32 AM EDT

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena. The gross proceeds from the offering... More

Workday (WDAY) PT Raised to $215 at Monness, Crespi, Hardt Following 1Q

May 28, 2020 8:26 AM EDT

Monness, Crespi, Hardt analyst Brian White raised the price target on Workday (NASDAQ: WDAY) to $215.00 (from $195.00) while maintaining a Buy rating following the company's 1Q earnings report. Workday reported 1Q sales of $1.018 billion that exceeded the Street at $1.002 billion, but EPS of $0.44... More

Workday (WDAY) PT Raised to $181 at Piper Sandler

May 28, 2020 8:08 AM EDT

Piper Sandler analyst Brent Bracelin raised the price target on Workday (NASDAQ: WDAY) to $181.00 (from $150.00) while maintaining a Neutral rating. Revenue increased 23% y/y, exceeding consensus by $13M with upside driven by healthy subscription growth of 25% y/y. Guidance for FY21 subscription... More

Semtech Corp. (SMTC) PT Raised to $63 at Piper Sandler Following 1Q

May 28, 2020 8:03 AM EDT

Piper Sandler analyst Harsh Kumar raised the price target on Semtech Corp. (NASDAQ: SMTC) to $63.00 (from $43.00) while maintaining a Overweight rating following the company's 1Q earnings report. In the April quarter, Semtech saw strength in the infrastructure market, but its other segments lagged due to... More

Semtech Corp. (SMTC) PT Raised to $50 at Susquehanna Following 1Q Report

May 28, 2020 7:44 AM EDT

Susquehanna analyst Christopher Rolland raised the price target on Semtech Corp. (NASDAQ: SMTC) to $50.00 (from $40.00) while maintaining a Neutral rating following the company's 1Q report. Semtech reported generally in-line results and better guidance, primarily as Signal Integrity was bolstered by strong Data Center, 10G... More

BioCryst Pharma (BCRX) Prices 18.7M Share Common Offering at $4.50/Sh; Announces Pricing of Pre-Funded Warrants Offering

May 28, 2020 5:51 AM EDT

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 18,711,113 shares of its common stock, offered at a price to the public of $4.50 per share. In addition, and in lieu of common stock, BioCryst is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of... More